Surface Oncology

$7.70 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Surface Oncology

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.

Stock Analysis

last close $7.7
1-mo return 29.2%
3-mo return 18.1%
avg daily vol. 1.53M
52-week high 14.4
52-week low 4.95
market cap. $352M
forward pe -
annual div. -
roe 13.9%
ltg forecast -
dividend yield -
annual rev. $90M
inst own. 59.8%

Subscribe now for daily local and international financial news